Talazoparib (Talzenna)

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 02:09, 17 October 2018 by Jwarner (talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Mechanism of action

PARP inhibitor

Diseases for which it is used

BRCA-mutated breast cancer

History of changes in FDA indication

10/16/2018: Initial approval " for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer."

Also known as

Code name: BMN-673
Brand name: Talzenna

Retrieved from "https://hemonc.org/w/index.php?title=Talazoparib_(Talzenna)&oldid=32029"